| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
PAPER |
1 Alzheimer's Disease Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
2 Department of Psychiatry
3 Department of Neurology
4 Department of Epidemiology
Correspondence to:
Correspondence to:
Dr O L Lopez, Neuropsychology Research Program, 3501 Forbes Avenue, Suite 830, Pittsburgh, PA 15213, USA
Methods: The short and long term effects of CEIs were evaluated in 135 patients with probable Alzheimer's disease relative to 135 patients who were never exposed to CEIs matched by age, education, duration of the symptoms, and cognitive status. We measured 1 year change in cognitive and functional performance, and the likelihood of arriving at each of four end points: (1) mini mental state examination (MMSE) of 9 or lower, (2) Blessed dementia rating scale for activities of daily living of 12 or higher, (3) nursing home admission, and (4) death, over an average 3 years of observation (36.7 (SD 21.5) months).
Results: Patients on CEIs were better cognitively and functionally after 1 year compared with those patients who never used CEIs. A proportional hazard analysis with CEI use as a time dependent covariate showed that the use of CEIs decreased the risk of nursing home admission. There was no association, however, between use of CEIs and time to cognitive and functional end points, or to death.
Conclusions: This observational study showed that there was an initial cognitive and functional benefit from the use of CEIs in Alzheimer's disease, which waned as the disease progressed. However, the results suggest that there is a long term beneficial effect of the use of CEIs, as indicated by the delay in adsmission to nursing homes.
Keywords: cholinesterase inhibitors; dementia; Alzheimer's disease
Abbreviations: CEIs, cholinesterase inhibitors; MMSE, mini mental state examination; HDRS, Hamilton depression rating scale; DSM-IV, statistical manual of mental disorders, fourth edition; EPS, extrapyramidal signs; BDRS, Blessed dementia rating scale; MDRS, Mattis dementia rating scale; CDR, clinical dementia rating; HRS, Hachinski rating scale;
This article has been cited by other articles:
|
|
 |
|
  J. L. Cummings, R. Doody, and C. Clark Disease-modifying therapies for Alzheimer disease: Challenges to early intervention Neurology, October 16, 2007; 69(16): 1622 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Becker, L. T. Mestre, S. Ziolko, and O. L. Lopez Gene-Environment Interactions With Cognition in Late Life and Compression of Morbidity Am J Psychiatry, June 1, 2007; 164(6): 849 - 852. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gillette-Guyonnet, S. Andrieu, F. Nourhashemi, E. Reynish, and B. Vellas RESPONSE TO LETTER FROM GARCIA AND COLLEAGUES ON CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2007; 62(6): 679 - 680. [Full Text] [PDF]
|
|
|
|
|
|
A. Garcia, K. Thompson, K. Zanibbi, S. Geick, and R. Adams CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2007; 62(5): 570 - 570. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lopez-Pousa, J. G. Olmo, J. V. Franch, A. T. Estrada, O. S. Cors, I. P. Nierga, and E. Gelada-Batlle Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age Ageing, July 1, 2006; 35(4): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gillette-Guyonnet, S. Andrieu, F. Cortes, F. Nourhashemi, C. Cantet, P.-J. Ousset, E. Reynish, H. Grandjean, and B. Vellas Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2006; 61(5): 516 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Marseille and D. H.S. Silverman Recognition and treatment of Alzheimer's disease: A case-based review American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 119 - 125. [Abstract] [PDF]
|
|
|
|
 |
|
 I Masse, R Bordet, D Deplanque, A Al Khedr, F Richard, C Libersa, and F Pasquier Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1624 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Feldman and M. Woodward The staging and assessment of moderate to severe Alzheimer disease Neurology, September 27, 2005; 65(6_suppl_3): S10 - S17. [Abstract] [Full Text]
|
|
|
|
|
|
M. Hashimoto, H. Kazui, K. Matsumoto, Y. Nakano, M. Yasuda, and E. Mori Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer's Disease? Am J Psychiatry, April 1, 2005; 162(4): 676 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Seltzer, P. Zolnouni, M. Nunez, R. Goldman, D. Kumar, J. Ieni, S. Richardson, and for the Donepezil "402" Study Group Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial Arch Neurol, December 1, 2004; 61(12): 1852 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Feldman, S. Gauthier, J. Hecker, B. Vellas, M. Hux, Y. Xu, E.M. Schwam, S. Shah, and V. Mastey Economic evaluation of donepezil in moderate to severe Alzheimer disease Neurology, August 24, 2004; 63(4): 644 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Salloway, S. Ferris, A. Kluger, R. Goldman, T. Griesing, D. Kumar, and S. Richardson Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial Neurology, August 24, 2004; 63(4): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Caplan and E. L. Harper Robine and Michel's "Looking Forward to a General Theory on Population Aging": Australia Is Still Aging Well J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2004; 59(6): M598 - M599. [Full Text] [PDF]
|
|
|
|
|
|
G Adler, S Brassen, K Chwalek, B Dieter, and M Teufel Prediction of treatment response to rivastigmine in Alzheimer's dementia J. Neurol. Neurosurg. Psychiatry, February 1, 2004; 75(2): 292 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Counts, S. E. Perez, S. D. Ginsberg, S. de Lacalle, and E. J. Mufson Galanin in Alzheimer Disease Mol. Interv., May 1, 2003; 3(3): 137 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Grossberg and A. K. Desai Management of Alzheimer's Disease J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M331 - 353. [Full Text] [PDF]
|
|
|
|
|
|
V.L. Wheelock, T. Tempkin, K. Marder, M. Nance, R.H. Myers, H. Zhao, E. Kayson, C. Orme, and I. Shoulson Predictors of nursing home placement in Huntington disease Neurology, March 25, 2003; 60(6): 998 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Michel, S. Pautex, D. Zekry, G. Zulian, and G. Gold End-of-Life Care of Persons With Dementia J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2002; 57(10): M640 - 644. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
